Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAINT: Anlotinib plus Icotinib in EGFR-mutant NSCLC
NCT04797806Phase 3Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04797806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797806.